Reported 20 days ago
Source: WSJ
Reported 20 days ago
Amrize Ltd., the newly formed North American cement company from Holcim Ltd., experienced a decline in its share price during its trading debut in Switzerland, closing down 15% at 39.31 Swiss francs. Despite being the largest cement provider in the US and Canada, Amrize's market volatility is anticipated as industry challenges arise, with analysts recommending a hold on shares.
Source: YAHOO
Reported 20 days ago
Source: WSJ
Reported 20 days ago
Prosus has decided to delay the IPO of its Indian payments and lending firm PayU, prioritizing the enhancement of business operations over the next six to twelve months, according to the company's CFO. Although there was an initial aim to list PayU by 2025, the focus will now be on improving the business in the coming year.
Source: YAHOO
Reported 20 days ago
Source: WSJ
Reported 20 days ago
President Trump's recent military actions against Iran have intensified uncertainties surrounding the Federal Reserve's monetary policy, as officials grapple with conflicting signals regarding future interest rate cuts. While some Fed policymakers advocate for immediate cuts due to concerns over inflation and economic growth, others believe that rising oil prices from the conflict could necessitate maintaining current rates longer. Federal Reserve Chair Jerome Powell has indicated a cautious approach, suggesting that historical patterns show energy price spikes often do not have lasting inflationary effects. As discussions continue, upcoming inflation reports will further inform the Fed's next decisions.
Source: YAHOO
Reported 20 days ago
Source: BARRONS
Reported 20 days ago
Recent escalating military actions between Israel and Iran have raised tensions globally, as Tehran threatens to retaliate against US strikes on its nuclear facilities. Iran's Islamic Revolutionary Guard Corps has fired missiles at Israel, while the US and Israel increase their attacks, further deepening concerns of a regional war. The situation has caused fluctuations in oil prices and impacted global markets, while international efforts to restore peace are complicated by Iran's isolation and the limitations of its allies.
Source: YAHOO
Reported 20 days ago
French private sector activity saw a further decline in June, as both the manufacturing and services sectors struggled, according to S&P Global. The services PMI fell to 48.7 and the manufacturing PMI dropped to 47.8, indicating contraction in both areas. Factors contributing to this downturn included excess client stock, difficult market conditions, and geopolitical tensions, particularly regarding tariffs and conflicts in the Middle East.
Source: YAHOO
Reported 20 days ago
Dutch technology investor Prosus has reported a 47% rise in full-year core earnings, reaching $7.4 billion, surpassing expectations due to its growth in food delivery and e-commerce. This marks a strategic shift from being purely an investment group to actively engaging in tech services. Prosus has secured most approvals for its acquisition of Just Eat Takeaway to strengthen its position in Europe and has reported a positive free cash flow for the first time.
Source: YAHOO
Reported 20 days ago
Source: WSJ
Reported 20 days ago
Gold experienced volatility as traders reacted to escalating tensions in the Middle East following US strikes on Iran. Despite an initial increase, gold prices fell to around $3,360 an ounce. While the ongoing conflict has potentially supported gold's rise this year, concerns of inflation from rising energy prices may negatively affect bullion. Analysts suggest that a combination of uncertainty and favorable monetary policies may keep gold prices near record levels in the near future.
Source: YAHOO
Reported 20 days ago
Global markets saw a slight downturn as investors await Iran's potential response to U.S. airstrikes on its nuclear facilities. Oil prices surged to five-month highs, while the dollar strengthened amid a cautious atmosphere. Analysts suggest that the market is currently perceiving the strikes as a contained incident rather than the onset of a wider conflict, though any sign of Iranian retaliation could alter this sentiment dramatically. The prevailing view among experts is one of volatility in the short term as the geopolitical situation unfolds.
Source: YAHOO
Reported 20 days ago
Source: BARRONS
Reported 20 days ago
Intellia Therapeutics presented promising three-year follow-up data from its Phase 1 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) at the EAACI Congress 2025. All 10 participants remained attack-free for a median of 23 months post-treatment, showing a 98% reduction in monthly HAE attacks. The ongoing Phase 3 HAELO trial is progressing well, with Intellia aiming for a BLA submission in 2026 and a potential product launch in 2027.
Source: YAHOO
Reported 20 days ago
Palo Alto Networks, the largest standalone cybersecurity firm, faces a unique challenge as it balances growth opportunities with the realities of market maturity. Although the company has seen nearly 9% growth this year and maintains a buy rating from analysts, revenue growth is slowing and customer retention is declining. Geopolitical tensions have heightened demand for cybersecurity solutions, yet the firm struggles with a plateau in customer adoption, indicating a potential shift in the industry landscape. As it navigates these challenges, Palo Alto remains resilient compared to the broader tech sector.
Source: YAHOO
Reported 20 days ago
Twist Bioscience Corporation has expanded its collaboration with Element Biosciences to enhance their Next Generation Sequencing (NGS) offerings. This partnership integrates Twist's library prep and target enrichment workflows with Element's AVITI™ devices and Trinity™ flowcells, making Twist the exclusive supplier of new Trinity kits for the AVITI platform. The aim is to streamline hybrid capture workflows in agbio, genomics, and clinical research, providing researchers with improved platform flexibility and quality.
Source: YAHOO
Reported 20 days ago
Eli Lilly and Company will acquire Verve Therapeutics for up to $1.3 billion, reflecting a 113% premium over Verve's recent share price. The deal, which could pay $10.50 per share in cash plus additional contingencies, is set to enhance Lilly's cardiometabolic pipeline with single-dose gene-editing therapies targeting cardiovascular diseases. Completion is expected by Q3 2025.
Source: YAHOO
Reported 20 days ago
10x Genomics has announced a global settlement with Bruker Corporation that resolves all patent litigation between the two companies. Under the agreement, Bruker will pay 10x Genomics $68 million in installments from Q3 2025 to Q2 2026, along with ongoing royalties on spatial biology products. The settlement includes patent cross-licenses and the resolution of all legal actions in the US, Germany, and the European Unified Patent Court, emphasizing the importance of intellectual property in fostering scientific innovation.
Source: YAHOO
Reported 20 days ago
Lake Street Capital has reaffirmed a Buy rating and $30 target price for ClearPoint, highlighting the potential impact of AMT-130, an experimental gene therapy for Huntington's disease developed by uniQure. With the FDA's expedited approval process in sight, AMT-130 could significantly enhance ClearPoint's financial prospects, given its associated high-value disposables. This regulatory progress may clarify ClearPoint's role in advancing gene therapy and neurosurgery, marking a pivotal moment for the company.
Source: YAHOO
Reported 20 days ago
Barclays has initiated coverage of BioMarin Pharmaceutical Inc. (BMRN) with a Buy rating and a price target of $86.00, as stated in a report by analyst Gena Wang. The company reported $745.15 million in revenue and $185.69 million in profits for the quarter ending March 31. Despite facing challenges in profitability due to high R&D costs, analysts remain optimistic about BioMarin's future growth potential due to its robust pipeline and strategic acquisition capabilities.
Source: YAHOO
Reported 20 days ago
Exact Sciences Corporation (NASDAQ:EXAS) has expanded the validation of its Oncodetect™ test for monitoring colorectal cancer recurrence, presenting new data from the Beta-CORRECT study at ASCO 2025. This research shows that patients with positive ctDNA results exhibit significantly higher recurrence risks. Additionally, the company plans to launch a next-generation test in 2026 using MAESTRO technology to enhance detection capabilities, marking a significant advance in molecular residual disease identification.
Source: YAHOO